United States

Infinity Pharmaceuticals Inc (INFI.O)

INFI.O on Nasdaq

27 Sep 2016
Change (% chg)

$0.02 (+1.31%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for INFI.O


Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145,... (more)


Beta: 1.86
Market Cap(Mil.): $75.87
Shares Outstanding(Mil.): 49.59
Dividend: --
Yield (%): --


  INFI.O Industry Sector
P/E (TTM): 5.28 42.41 36.20
EPS (TTM): 0.29 -- --
ROI: 9.63 -0.33 13.87
ROE: 14.39 -3.14 14.78

BRIEF-Infinity Pharma Q2 earnings per share $1.05

* Infinity provides company update and reports second quarter 2016 financial results

Aug 09 2016

BRIEF-Infinity Pharmaceuticals sees workforce restructuring completed by year-end

* Expects to incur severance, benefits and related costs of about $8 million

Jun 28 2016

BRIEF-Infinity regains worldwide rights to duvelisib; ends collaboration with AbbVie

* Says neither infinity nor abbvie have future financial obligations to other party

Jun 28 2016

BRIEF-Infinity Pharmaceuticals expects to incur total restructuring costs of about $6 to $8 mln

* Expects restructuring to be substantially completed by july 1, 2016 and to be fully completed by december 31, 2016

Jun 14 2016

BRIEF-Infinity Pharmaceuticals Inc reports topline results from DYNAMO(tm)

* Majority of reported side effects were reversible and clinically manageable.

Jun 14 2016

BRIEF-Infinity Pharmaceuticals reports Q1 loss per share $0.82

* Infinity provides company update and reports first quarter 2016 financial results

May 04 2016

BRIEF-Infinity Pharma announces new preclinical data for IPI-549

* Preclinical data demonstrate that ipi-549 targets immune cells, alters immune-suppressive microenvironment Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Apr 18 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
Provider : Stock Traders Daily
Provider : New Constructs, LLC
Provider : ValuEngine, Inc.
Provider : S&P Capital IQ Quantitative Report

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.